BridgeMD
Compares treatment options for Critical Illness
Official title Comparing High-protein Vs. Standard Protein Nutritional Support in Critically Ill Patients At Risk for Refeeding Syndrome
ClinicalTrials.gov ID: NCT06825377
What this study is testing
- What it's testing
- The goal of this clinical trial is to determine the optimal protein administration strategy for enhancing both nutritional and clinical outcomes, as well as reducing complications and mortality in ICU patients at risk for refeeding syndrome (RS). This study will include critically ill patients at risk for RS who are receiving supportive nutrition.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Willingness to cooperate and complete the informed consent form by the patient or legal guardian;
- age ≤ 18 years and \< 65 years;
- Non-pregnant and non-lactating;
- Serum creatinine ≥ 1.1 mg/dl for women and ≥ 1.2 mg/dl for men;
- No organ failure at the time of study enrollment;
You likely can't join if
- Unwillingness to continue cooperation during study;
- Discharge or death of the patient earlier than 5 days from the start of the intervention;
- Occurrence of side effects during the study
See the full eligibility criteria
- Willingness to cooperate and complete the informed consent form by the patient or legal guardian;
- age ≤ 18 years and \< 65 years;
- Non-pregnant and non-lactating;
- Serum creatinine ≥ 1.1 mg/dl for women and ≥ 1.2 mg/dl for men;
- No organ failure at the time of study enrollment;
- Intervention initiation within 48 hours of ICU admission;
- No history of metastatic cancer or end-stage disease;
- No absolute contraindications to enteral nutrition (e.g., persistent ileus, gastrointestinal ischemia, persistent or biliary vomiting, mechanical obstruction);
- No active infections, sepsis, severe sepsis, or septic shock;
- No intolerance to the whey protein supplement used in the current study;
- Not participating in other clinical trials concurrently with this study;
- No clinical conditions with higher or lower protein needs, such as burns, sepsis, cirrhosis, or chronic kidney disease;
- No diabetes with severe complications such as ketoacidosis, hyperosmolar coma, or acidosis.
- Unwillingness to continue cooperation during study;
- Discharge or death of the patient earlier than 5 days from the start of the intervention;
- Occurrence of side effects during the study
The study team makes the final eligibility decision.
Where it's taking place
- Tehran, Iran
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tehran, Iran. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.